Compare LOAN & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | CPIX |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 59.5M |
| IPO Year | 1999 | 2009 |
| Metric | LOAN | CPIX |
|---|---|---|
| Price | $4.50 | $3.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.2K | ★ 216.1K |
| Earning Date | 03-11-2026 | 03-03-2026 |
| Dividend Yield | ★ 10.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $7,138,128.00 | ★ $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $9.87 | ★ N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $4.29 | $1.85 |
| 52 Week High | $6.05 | $7.25 |
| Indicator | LOAN | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 42.57 |
| Support Level | $4.48 | $3.84 |
| Resistance Level | $4.69 | $4.92 |
| Average True Range (ATR) | 0.12 | 0.47 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 16.22 | 2.99 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.